NasdaqCM:NAGEPersonal Products
A Look At Niagen Bioscience (NAGE) Valuation As New Partner Launches And Clinical Data Gain Attention
Recent coverage around Niagen Bioscience (NAGE) has focused on upcoming launches with major consumer product partners and fresh clinical data tied to its FDA recognized nicotinamide riboside, which has pushed the stock back onto investors’ watchlists.
See our latest analysis for Niagen Bioscience.
Despite the recent excitement around new partner launches and clinical readouts, Niagen Bioscience’s share price has pulled back. The 30 day share price return shows a 24.11% decline and the 90 day...